重组人促红细胞生成素对急性缺血性脑卒中患者安全性的研究  

The Study on Safety of Recombinant Human Erythropoietin in Treatment of Acute Ischemic Stroke

作　　者：薛炬君[1] 陈曦[1] 

机构地区：[1]黑龙江省医院老年神经内科,黑龙江哈尔滨150036

出　　处：《中国继续医学教育》2016年第10期123-124,共2页China Continuing Medical Education

摘　　要：目的分析对急性缺血性脑卒中患者实施重组人促红细胞生成素治疗的安全性。方法收集我院接受诊治的脑卒中患者50例,在常规治疗基础上,研究组患者皮下注射重组人促红细胞生成素,对照组患者皮下注射生理盐水。结果研究组患者的治疗有效率较对照组略有升高,血细胞积压水平,死亡风险率均较对照组无明显差异。结论对急性缺血性脑卒中患者实施重组人促红细胞生成素治疗可以一定程度上起到神经保护方面的作用,同时未见明显死亡率的增加和红细胞压积水平的升高。Objective To analyze the safety of recombinant human erythropoietin on the patients with acute ischemic stroke patients with hormone treatment.Methods We selected 50 cases of acute ischemic stroke admmited in our hospital to accept the diagnosis and treatment.On the basis of routine treatment,the patients of the study group under the skin injected recombinant human erythropoietin,while that of the control group injected saline.Results The effective rate of patients in the study group was slightly higher than that of the control group,the level of blood cell backlogand the risk of death was no significant difference compared with the control group.Conclusion For patients suffering from acute ischemic cerebral apoplexy,the implementation of recombinant human erythropoietin treatment can play a neuroprotective role to a certain extent,and there was no significant increase in mortality and red blood cell pressure accumulation level increased.

关 键 词：重组人促红细胞生成素 急性缺血性脑卒中 安全性 

分 类 号：R971[医药卫生—药品]